What is MobileODT?
Founded in 2012 and headquartered in Tel Aviv, Israel, MobileODT specializes in the development of AI-powered colposcopy and visual assessment technologies. The company's core mission is to bridge the gap in women's health by providing clinicians with portable, high-resolution imaging devices that utilize cloud-based analytics to improve diagnostic accuracy. By digitizing the colposcopy process, MobileODT enables real-time decision support, which is critical for early detection and effective treatment planning in resource-constrained settings. The firm's market position is defined by its commitment to clinical excellence and its ability to transform traditional medical hardware into intelligent, data-rich diagnostic ecosystems.
How much funding has MobileODT raised?
MobileODT has raised a total of $10.8M across 2 funding rounds:
Series B
$6.8M
Series C
$4M
Series B (2017): $6.9M with participation from Tristel and OrbiMed Advisors LLC
Series C (2020): $4M led by Tara Health, Laerdal, Tristel, and OrbiMed Israel Partners
Key Investors in MobileODT
OrbiMed Advisors LLC
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
Tristel
Tristel is a global leader in infection prevention and contamination control, providing specialized solutions that support clinical safety and hygiene standards in medical environments.
Laerdal
Laerdal is a prominent healthcare organization dedicated to helping save lives through the development of innovative training and simulation solutions for medical professionals.
What's next for MobileODT?
With the infusion of this latest capital, MobileODT is poised to accelerate its product roadmap and expand its footprint in international markets. The strategic focus will likely center on enhancing the diagnostic capabilities of its AI algorithms and deepening integration with existing electronic health record systems. As the company transitions into its next phase of maturity, the emphasis will shift toward scaling commercial operations and fostering partnerships with global health organizations. By maintaining a rigorous focus on clinical validation and user-centric design, MobileODT is well-positioned to lead the digital transformation of women's health diagnostics, ultimately improving patient outcomes through precision medicine and accessible technology.
See full MobileODT company page
